相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
2
100.0%
暂无批准数据
- Marengo Therapeutics has nominated the first development candidate under its June 2024 TriSTAR strategic collaboration with Ipsen, marking the second TriSTAR program to enter IND-enabling development. - The TriSTAR platform employs a differentiated two-in-one mechanism combining selective Vβ T-cell activation and tumor-directed engagement to overcome limitations of traditional CD3-directed T-cell engagers. - Saso Cemerski, Ph.D., formerly Head of Discovery Immune Cell Engagement at AstraZeneca, has been appointed Senior Vice President, Head of Immunology to accelerate pipeline expansion. - Ipsen will assume responsibility for all activities following the development candidate nomination, with Marengo eligible for milestone payments under the collaboration.
- Cue Biopharma completed a strategic financing round in December 2025 and established an exclusive licensing agreement with ImmunoScape, marking a significant pivot in the company's immunotherapy development strategy. - The company's CUE-401 program has gained broader scientific validation over the past year, though market sentiment remains cautious as investors await concrete operational updates and clinical progress. - With annual financials approaching, investor focus has intensified on cash burn rates and efficient capital allocation to fund operations through upcoming clinical data readouts without requiring additional equity dilution. - The biotechnology investment landscape in early 2026 has become highly selective, with institutional capital favoring companies that demonstrate clear milestones alongside secure financing capabilities.
- Cue Biopharma and ImmunoScape have formed a strategic collaboration to develop a breakthrough "Seed-and-Boost" immunotherapy approach combining TCR-engineered T cells with IL-2 Immuno-STAT molecules for solid tumor treatment. - The novel approach involves administering minimal doses of tumor-specific TCR-T cells followed by targeted IL-2 delivery to enable in vivo expansion and activation while reducing manufacturing complexity and systemic toxicity. - Compelling preclinical data in pancreatic and ovarian cancer models supports the clinical potential, with IND-enabling studies planned for 2027 submission. - Under the agreement, Cue Biopharma will receive $15 million upfront, a 40% equity stake in ImmunoScape, and high-single-digit royalty payments on future net sales.
- Cue Biopharma has appointed Dr. Usman Azam as President and CEO, effective September 29, 2025, bringing over 25 years of drug development experience including CAR-T cell therapy leadership at Novartis. - The company is strategically pivoting to prioritize autoimmune disease development, focusing on advancing its first-in-class tolerogenic biologic CUE-401 into clinical trials. - CUE-401 is designed as a bifunctional molecule combining TGF-beta with IL-2 mutein to restore immune homeostasis and tolerance, with potential to disrupt standard autoimmune disease treatment. - The leadership transition positions the company to address significant unmet medical needs in autoimmune diseases while seeking strategic partnerships for its clinical-stage CUE-100 series assets.
- BioNTech's BNT113, an mRNA cancer vaccine targeting HPV16+ oncoproteins E6 and E7, is being evaluated in the Phase 2 AHEAD-MERIT trial combined with pembrolizumab versus pembrolizumab alone for unresectable recurrent or metastatic HPV+ head and neck squamous cell carcinoma. - The vaccine demonstrated potent antigen-specific T cell responses in the investigator-initiated Phase 1/2 HARE-40 basket trial in patients with HPV16+ cancers. - Cue Biopharma's CUE-101, a targeted IL-2-based immunotherapy, has shown clinical activity and favorable tolerability as monotherapy in Phase 1 trials for HPV16+ recurrent/metastatic head and neck squamous cell carcinoma. - The HPV+ recurrent/metastatic head and neck cancer pipeline includes over 5 active companies developing targeted therapies, with multiple promising candidates advancing through clinical development.
- Cue Biopharma has dosed the first patient with CUE-102 in a Phase 1b investigator-sponsored trial for recurrent glioblastoma multiforme at Dana-Farber Cancer Institute. - The study evaluates CUE-102, an IL-2-based biologic targeting Wilms' Tumor 1 protein, in patients with glioblastoma at first recurrence under the leadership of Dr. David Reardon. - CUE-102 demonstrated favorable tolerability with no dose-limiting toxicities in previous Phase 1 trials for other WT1-expressing cancers including colorectal and pancreatic tumors. - Glioblastoma affects approximately 13,000 new patients annually in the US with median survival of 12-15 months and less than 5% five-year survival rate.
- Cue Biopharma's CUE-101 combined with pembrolizumab demonstrated a 50% overall response rate in patients with recurrent/metastatic HPV+ head and neck squamous cell carcinoma, significantly outperforming historical pembrolizumab monotherapy data. - The combination therapy showed remarkable survival benefits with 12-month overall survival of 88% and median overall survival of 32 months, compared to 57% and 12.3 months respectively with pembrolizumab alone. - An additional complete response was observed in a patient with multiple tumor sites, including lung metastases that cleared before the target lesion achieved complete response. - The therapy maintained efficacy across different PD-L1 expression levels, achieving 50% response rates even in patients with low combined positive scores (1-19).
- Cue Biopharma received positive Pre-IND feedback from the FDA for CUE-401, a first-in-class bispecific fusion protein designed to treat autoimmune diseases by inducing regulatory T cells. - The FDA reviewed the company's first-in-human trial design, dose escalation plan, and safety monitoring protocols, enabling Cue Biopharma to proceed with IND filing after completing final enabling studies. - CUE-401 combines TGF-β and IL-2 activities to convert autoreactive T cells into regulatory T cells, potentially establishing immune tolerance across multiple autoimmune conditions. - The novel therapy aims to provide durable immune rebalance by creating a "tolerance positive feedback loop" that specifically targets disease-causing autoantigens.
- Boehringer Ingelheim and Cue Biopharma have formed a strategic partnership to develop CUE-501, a first-in-class bispecific therapy designed to selectively deplete disease-causing B cells in autoimmune conditions. - The collaboration includes $12 million upfront payment to Cue Biopharma, with potential milestone payments reaching $345 million plus royalties, significantly strengthening Boehringer's immunology pipeline. - CUE-501 utilizes Cue's proprietary Immuno-STAT™ platform to engage virus-specific memory T cells against targeted B cells, potentially offering superior efficacy and safety compared to existing B cell-depleting therapies.
- CUE-101 combined with pembrolizumab demonstrates a 46% objective response rate and a 91.3% 12-month overall survival rate in first-line HPV+ R/M HNSCC patients. - In first-line patients with low PD-L1 expression, CUE-101 and pembrolizumab achieved a 50% objective response rate, indicating potential efficacy in challenging cases. - CUE-102 monotherapy shows a 67% overall disease control rate in late-stage pancreatic cancer, including an unconfirmed partial response with a 40% tumor reduction. - Both CUE-101 and CUE-102 exhibit favorable tolerability profiles with manageable adverse events, supporting their potential as safe and effective cancer therapies.
